---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-091856"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2022-03-31T23:59:59+00:00"
generated_at: "2026-06-26T12:42:13.724737+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IO Biotech reports FY2021 net loss of $67.9M; cash of $211.5M supports operations into mid-2024

## Summary
- Net loss $67.9M in FY2021 vs $12.0M in FY2020; R&D expenses rose to $30.2M from $8.5M.
- Cash and cash equivalents of $211.5M at Dec 31, 2021; expected runway through multiple data readouts into mid-2024.
- Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 + KEYTRUDA in advanced melanoma began patient recruitment.
- Updated Phase 1/2 data (MM1636) in metastatic melanoma to be presented at AACR 2022.
- Management notes longer-than-expected lead times in clinical site activation and patient enrollment.

## SEC filing metadata
- accession: 0001193125-22-091856
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2022-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312522091856/0001193125-22-091856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312522091856/d342643d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-091856
- JSON: https://secwatch.observer/filing/0001193125-22-091856.json
- Plain text: https://secwatch.observer/filing/0001193125-22-091856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.